genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2011
Tibotec Pharmaceuticals
Infectious Diseases
BMS, Tibotec to Combine Anti-HCV Candidates in Phase II Trial
Infectious Diseases
Gilead and Tibotec Expand HIV Drug Development Arrangement
Infectious Diseases
FDA Approves Gilead’s Single-Tablet Triple HIV Therapy Complera
Infectious Diseases
Pharmasset and Tibotec to Carry Out Combination Study in Chronic HCV
Drug Discovery
Tibotec and Gilead Partner to Combine HIV-1 Drugs into Single-Tablet Formulation
News
Pivotal Trials Show Tibotec’s HIV Drug Halves Rate of Treatment Withdrawal
News
Gilead and Tibotec Ink Pact to Develop Once-Daily HIV Therapy
Infectious Diseases
TB Alliance Partners with Tibotec to Advance Discovery and Development
News
Medivir Receives a $3.3M Milestone Fee from Tibotec in HCV Collaboration
News
Tibotec to Pay Medivir $24.5M in Connection with HCV Partnership
Scroll Up